Interference of antibacterial agents with phagocyte functions: immunomodulation or "immuno-fairy tales"?
Professional phagocytes (polymorphonuclear neutrophils and monocytes/macrophages) are a main component of the immune system. These cells are involved in both host defenses and various pathological settings characterized by excessive inflammation. Accordingly, they are key targets for immunomodulatory drugs, among which antibacterial agents are promising candidates. The basic and historical concepts of immunomodulation will first be briefly reviewed. Phagocyte complexity will then be unravelled (at least in terms of what we know about the origin, subsets, ambivalent roles, functional capacities, and transductional pathways of this cell and how to explore them). The core subject of this review will be the many possible interactions between antibacterial agents and phagocytes, classified according to demonstrated or potential clinical relevance (e.g., neutropenia, intracellular accumulation, and modulation of bacterial virulence). A detailed review of direct in vitro effects will be provided for the various antibacterial drug families, followed by a discussion of the clinical relevance of these effects in two particular settings: immune deficiency and inflammatory diseases. The prophylactic and therapeutic use of immunomodulatory antibiotics will be considered before conclusions are drawn about the emerging (optimistic) vision of future therapeutic prospects to deal with largely unknown new diseases and new pathogens by using new agents, new techniques, and a better understanding of the phagocyte in particular and the immune system in general.
Labro
M T
MT
INSERM U 479, Faculté Xavier Bichat, 75018 Paris, France. labro@bichat.inserm.fr
D000276:Adjuvants, Immunologic; D000900:Anti-Bacterial Agents / Q000276:immunology / Q000494:pharmacology* / Q000627:therapeutic use; D001419:Bacteria / Q000276:immunology; D001424:Bacterial Infections / Q000188:drug therapy / Q000276:immunology* / Q000382:microbiology; D006801:Humans; D007155:Immunologic Factors / Q000276:immunology / Q000494:pharmacology* / Q000627:therapeutic use; D010586:Phagocytes / Q000187:drug effects* / Q000276:immunology* / Q000502:physiology
D000276:Adjuvants, Immunologic; D000900:Anti-Bacterial Agents; D007155:Immunologic Factors